These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 22653033)

  • 1. [Is SSBT associated with atypical femoral fracture? SSBT is associated with atypical femoral fracture - pathophysiology of atypical femoral fractures - ].
    Mashiba T
    Clin Calcium; 2012 Jun; 22(6):914-8. PubMed ID: 22653033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Is SSBT associated with atypical femoral fracture? SSBT isn't associated with atypical femoral fracture].
    Soen S
    Clin Calcium; 2012 Jun; 22(6):919-22. PubMed ID: 22653034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [SSBT (severely suppressed bone turnover) ].
    Mori S
    Clin Calcium; 2013 Mar; 23(3):365-70. PubMed ID: 23445889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atypical femoral fractures and their relation to bisphosphonate use.
    Tripto-Shkolnik L
    Isr Med Assoc J; 2013 Aug; 15(8):447-50. PubMed ID: 24079069
    [No Abstract]   [Full Text] [Related]  

  • 5. [Morphological analysis of bone dynamics and metabolic bone disease. Does bisphosphonate treatment cause severely suppressed bone turnover (SSBT) ?].
    Kondo N; Yoda T
    Clin Calcium; 2011 Apr; 21(4):583-7. PubMed ID: 21447926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Atypical femoral fractures in long-term osteoporotic treatment with bisphosphonates].
    Thein R; Tenenbaum S; Chechick O; Hershkovitz O; Chechik A; Caspi I
    Harefuah; 2012 Sep; 151(9):532-6, 555. PubMed ID: 23367748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates in the treatment of osteoporosis.
    Diab DL; Watts NB
    Endocrinol Metab Clin North Am; 2012 Sep; 41(3):487-506. PubMed ID: 22877426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required?
    McClung M
    Clin Obstet Gynecol; 2013 Dec; 56(4):743-8. PubMed ID: 24177063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of atypical femoral fractures with bisphosphonate use by patients with varus hip geometry.
    Hagen JE; Miller AN; Ott SM; Gardner M; Morshed S; Jeray K; Alton TB; Ren D; Abblitt WP; Krieg JC
    J Bone Joint Surg Am; 2014 Nov; 96(22):1905-9. PubMed ID: 25410509
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the optimal duration of bisphosphonate therapy?
    Ott SM
    Cleve Clin J Med; 2011 Sep; 78(9):619-30. PubMed ID: 21885695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atypical diaphyseal femur fractures in patients with prolonged administration of bisphosphonate medication for osteoporosis.
    Horning JA; Czajka J; Uhl RL
    Orthopedics; 2010 Dec; 33(12):902. PubMed ID: 21117565
    [No Abstract]   [Full Text] [Related]  

  • 12. [New development in bisphosphonate treatment. When and how long should patients take bisphosphonates for osteoporosis?].
    Yamaguchi T; Sugimoto T
    Clin Calcium; 2009 Jan; 19(1):38-43. PubMed ID: 19122263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Are bisphosphonates associated with an increased risk of atypical femoral fractures as a class?
    Pazianas M
    JAMA Intern Med; 2013 Jan; 173(1):79-80. PubMed ID: 23318593
    [No Abstract]   [Full Text] [Related]  

  • 14. Atypical femur fracture during bisphosphonate drug holiday: a case series.
    Lovy AJ; Koehler SM; Keswani A; Joseph D; Hasija R; Ghillani R
    Osteoporos Int; 2015 Jun; 26(6):1755-8. PubMed ID: 25832177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term bisphosphonate usage and subtrochanteric insufficiency fractures: a cause for concern?
    Yoon RS; Hwang JS; Beebe KS
    J Bone Joint Surg Br; 2011 Oct; 93(10):1289-95. PubMed ID: 21969423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Bisphosphonate therapy for osteoporosis and bone strength].
    Kishimoto H
    Clin Calcium; 2006 Sep; 16(9):1513-19. PubMed ID: 16951477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A controversy: linking atypical femoral fractures to bisphosphonate therapy.
    Trotter CC; Pfister AK; Whited BA; Goldberg TH; Artz SA
    W V Med J; 2011; 107(2):8-13. PubMed ID: 21476471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of bone microarchitecture in postmenopausal women on long-term bisphosphonate therapy with atypical fractures of the femur.
    Zanchetta MB; Diehl M; Buttazzoni M; Galich A; Silveira F; Bogado CE; Zanchetta JR
    J Bone Miner Res; 2014 Apr; 29(4):999-1004. PubMed ID: 24115250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bisphosphonate-related atypical femoral fracture: Managing a rare but serious complication.
    Silverman S; Kupperman E; Bukata S
    Cleve Clin J Med; 2018 Nov; 85(11):885-893. PubMed ID: 30395525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atypical femoral fractures during prolonged use of bisphosphonates: short-term responses to strontium ranelate and teriparatide.
    Carvalho NN; Voss LA; Almeida MO; Salgado CL; Bandeira F
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2675-80. PubMed ID: 21752890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.